Form 8-K - Current report:
SEC Accession No. 0000950170-22-002296
Filing Date
2022-02-28
Accepted
2022-02-28 16:14:56
Documents
14
Period of Report
2022-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tptx-20220228.htm   iXBRL 8-K 55444
2 EX-99.1 tptx-ex99_1.htm EX-99.1 210920
3 GRAPHIC img27621221_0.jpg GRAPHIC 13689
  Complete submission text file 0000950170-22-002296.txt   412388

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tptx-20220228_lab.xml EX-101.LAB 12890
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tptx-20220228_pre.xml EX-101.PRE 9557
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tptx-20220228.xsd EX-101.SCH 2513
8 EXTRACTED XBRL INSTANCE DOCUMENT tptx-20220228_htm.xml XML 4553
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

EIN.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 22689724
SIC: 2834 Pharmaceutical Preparations